News

Under the deal, Allergan investors would receive $48.30 in cash and 0.83 of a Valeant stock for each share they own. Ackman’s Pershing Square Capital Management (Pershing Square),

The trial is designed to evaluate the contribution of the ICS component on lung function, in patients with Chronic Obstructive Pulmonary Disease (COPD). According to GSK, positive results

Orphan drug status provides incentives to the BioThrax PEP Program, including the waiver of the Biologics License Application (BLA) supplemental regulatory filing fee and marketing exclusivity of up

As part of the option agreement, Amunix will receive an upfront $1m payment and will also be eligible to receive up to $38m in clinical and commercial milestone

For the 12 months ending February 2014, the US market for Adenosine Injection, USP approximated $28m, according to IMS. As with all products in the company’s portfolio, Adenosine

As part of the deal, Novartis would have opt-in rights to GSK’s current and future oncology R&D pipeline. The deal will see Novartis divest its Vaccines business (excluding

The company said that in this case, the patent will be for the treatment of patients suffering a stroke. Researchers at the Henry Ford Hospital in Detroit, US,

The company is developing ceftolozane/tazobactam for the treatment of certain Gram-negative infections. The NDA is based on positive data from pivotal Phase III clinical trials in cUTI and

The multi-year partnership will deliver significant savings by driving distribution efficiencies to their nationwide locations over the term of the agreement. CTCA corporate supply chain manager Clinton Hazziez